ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 198 filers reported holding ROYALTY PHARMA PLC in Q4 2020. The put-call ratio across all filers is 2.07 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $85,002 | -16.4% | 3,132 | -5.3% | 0.00% | 0.0% |
| Q2 2023 | $101,719 | -24.6% | 3,309 | -11.6% | 0.00% | 0.0% |
| Q1 2023 | $134,860 | -10.8% | 3,743 | -2.2% | 0.00% | 0.0% |
| Q4 2022 | $151,204 | -2.4% | 3,826 | -0.6% | 0.00% | 0.0% |
| Q3 2022 | $155,000 | -3.7% | 3,851 | +0.3% | 0.00% | 0.0% |
| Q2 2022 | $161,000 | -18.3% | 3,841 | -23.9% | 0.00% | 0.0% |
| Q1 2022 | $197,000 | -2.5% | 5,044 | -0.7% | 0.00% | 0.0% |
| Q4 2021 | $202,000 | +6.3% | 5,080 | -3.4% | 0.00% | 0.0% |
| Q3 2021 | $190,000 | -19.1% | 5,259 | -8.2% | 0.00% | 0.0% |
| Q2 2021 | $235,000 | +2.2% | 5,727 | +8.7% | 0.00% | 0.0% |
| Q1 2021 | $230,000 | +132.3% | 5,270 | +166.8% | 0.00% | – |
| Q4 2020 | $99,000 | +47.8% | 1,975 | +24.4% | 0.00% | – |
| Q3 2020 | $67,000 | – | 1,587 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |